JUNS

Jupiter Neurosciences Inc

0.1746

Jul 22 • 03:59PM ET +0.0049 (2.89%)

0.1671

Aftermarket • 05:23PM ET -0.0075 (-4.30%)

Healthcare Biotechnology USA Nano NASD

Jul 21, 7:15 AMJupiter Neurosciences inks perpetual exclusive U.S. ALA-002 license deal valued up to $100 million including milestones and royalties

Peers: APRE BCDA BIVI CALC CVM GOVX KAPA KPRX LNAI NEUP

| Held by: VXF

Scroll to Statements

Index	-
Market Cap	8.42M
Enterprise Value	10.92M
Income	-9.18M
Sales	0.04M
Book/sh	-0.08
Cash/sh	0.05
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	5
IPO	Dec 03, 2024

P/E	-
Forward P/E	-
PEG	-
P/S	210.40
P/B	-
P/C	3.57
P/FCF	-
EV/EBITDA	-
EV/Sales	272.90
Quick Ratio	0.48
Current Ratio	0.51
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-0.27
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	-18.29% -7.78%
Sales past 3/5Y	- -
EPS Y/Y TTM	-166.53%
Sales Y/Y TTM	-
EPS Q/Q	-26.62%
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	0.00% -

Insider Own	36.98%
Insider Trans	0.00%
Inst Own	3.95%
Inst Trans	4.35%
ROA	-205.98%
ROE	-6529.17%
ROIC	-
Gross Margin	78.76%
Oper. Margin	-23075.85%
Profit Margin	-22690.83%
SMA20	-13.60%
SMA50	-27.02%
SMA200	-75.34%
Trades

Shs Outstand	36.28M
Shs Float	30.39M
Short Float	3.09%
Short Ratio	0.07
Short Interest	0.94M
52W High	1.85 -90.56%
52W Low	0.16 12.64%
Volatility	17.49% 12.35%
ATR (14)	0.03
RSI (14)	36.83
Beta	1.75
Rel Volume	1.81
Avg Volume	12.92M
Volume	23,398,858

Perf Week	-2.18%
Perf Month	-24.09%
Perf Quarter	-62.47%
Perf Half Y	-80.60%
Perf YTD	-82.88%
Perf Year	-89.67%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	25.00
Prev Close	0.17
Price	0.17
Change	2.89%

Today 01:25PM	Psychedelic Therapy Meets M&A: Fireside Chat with Jupiter Neurosciences CEO Christer Rosén & President Alison Silva (IPO-Edge.com)
01:25PM	Psychedelic Therapy Meets M&A: Fireside Chat with Jupiter Neurosciences CEO Christer Rosen & President Alison Silva (Ipo Edge)
Jul-21-26 10:27AM	Jupiter Neurosciences Signs ALA-002 License Agreement Worth Up to $100 Million (NASDAQ:JUNS) (InvestorsHub)
07:13AM	Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million (GlobeNewswire)
Jul-07-26 08:58AM	Jupiter Neurosciences Strengthens Board with Appointment of Dr. Tomas J. Philipson (GlobeNewswire)
07:30AM	Loading…
May-27-26 07:30AM	Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson's Disease (GlobeNewswire)
May-26-26 12:00PM	D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. (Nasdaq:JUNS) in Connection with its ~$2 Million Registered Direct Offering (ACCESSWIRE)
May-21-26 05:15PM	Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering (GlobeNewswire) +32.10% -12.19%
May-20-26 02:38PM	Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering (GlobeNewswire) -35.94%
11:12AM	PharmAla Biotech Signs Term Sheet for $100 Million U.S. Licensing Deal for ALA-002 MDMA Therapy (MDXXF) (InvestorsHub)
07:38AM	Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech (GlobeNewswire)
May-04-26 11:30AM	Jupiter Neurosciences, Inc. to Present at The Market Movers Investor Summit (Newsfile)
Apr-13-26 08:00PM	Jupiter Neurosciences, Inc. to Present at Centri Capital Conference on April 14 (Newsfile)
Apr-07-26 08:00AM	Jupiter Neurosciences Appoints Kristopher Fishman and Sanjiv Lal to Nugevia Advisory Board (GlobeNewswire)
Mar-31-26 12:00PM	Jupiter Neurosciences to Present at Emerging Growth Conference on April 2 (GlobeNewswire) +15.83%
08:00AM	Loading…
Mar-02-26 08:00AM	Jupiter Neurosciences to Present at BIO Investment and Growth Summit 2026 (GlobeNewswire)
Feb-25-26 08:30AM	Jupiter Neurosciences Invited to Present Clinical and Commercial Progress at Investor Dinner at Mar-a-Lago (GlobeNewswire)
Feb-23-26 09:30AM	Jupiter Neurosciences Amends Yorkville Installment Provisions to Align Capital With Clinical and Commercial Execution (GlobeNewswire)
Feb-12-26 01:07PM	Jupiter Neurosciences Selected as B2i Digital Featured Company (NewMediaWire) -5.08%
Jan-28-26 06:00AM	Jupiter Neurosciences Expands Nugevia Addressable Market with Focus on GLP-1 Users (GlobeNewswire) -23.53%
Jan-27-26 10:45AM	Jupiter Neurosciences Presenting at the 3rd Annual DealFlow Discovery Conference (ACCESSWIRE)
Dec-23-25 08:00AM	Join Jupiter Neurosciences' Exclusive Live Investor Webinar and Q&A Session on January 6 (GlobeNewswire)
Dec-10-25 02:29PM	$50B+ Longevity Opportunity: Jupiter Neurosciences CEO Christer Rosen & President Alison Silva, Live at Nasdaq (Exec Edge)
Dec-03-25 08:00AM	Jupiter Neurosciences Marks Transformational First Year as a Public Company, Entering 2026 with Powerful Clinical and Commercial Momentum (GlobeNewswire)
Dec-02-25 04:15PM	Jupiter Neurosciences to Participate in NobleCon21 (Newsfile)
Nov-05-25 08:30AM	Jupiter Neurosciences Receives FDA Clearance of IND Application to Initiate Phase 2a Clinical Trial of JOTROL in Parkinson's Disease (GlobeNewswire) +8.80%
Oct-27-25 08:30AM	Jupiter Neurosciences Enters into Agreements for up to $20 Million in Flexible Financing (GlobeNewswire) +11.11%
Sep-15-25 08:00AM	Jupiter Neurosciences Names Visionary Entrepreneur and Biohacker Jean Fallacara as Third Nugevia Brand Ambassador (GlobeNewswire) +5.26%
Aug-26-25 08:00AM	Jupiter Neurosciences Launches Nugevia Website and Opens Pre-Orders for Groundbreaking Longevity Supplements (GlobeNewswire)
Aug-19-25 08:12AM	Jupiter Neurosciences Names NBA Legend Chris Webber as Second Nugevia Brand Ambassador (GlobeNewswire)
08:00AM	Loading…
Aug-11-25 08:00AM	Jupiter Neurosciences Introduces Nugevia MND: A Cognitive Health Supplement Leveraging Clinically Validated Neuroscience (GlobeNewswire)
Jul-23-25 08:00AM	Jupiter Neurosciences Highlights Critical Advancement of JOTROL Over Traditional Resveratrol with Breakthrough Bioavailability and CNS-Targeted Science (GlobeNewswire)
Jul-10-25 04:05PM	Jupiter Neurosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire) +18.63% +19.90%
Jun-30-25 03:15PM	Jupiter Neurosciences Showcases Nugevia PWR: Mitochondrial Optimization Supplement Designed to Boost Energy, Endurance, and Recovery (GlobeNewswire)
Jun-27-25 08:00AM	Jupiter Neurosciences Unveils Nugevia GLO: A Breakthrough in Cellular Skin Health, Backed by Patented Pharmaceutical Science (GlobeNewswire)
Jun-23-25 08:00AM	Jupiter Neurosciences Names Golf Legend Annika Sörenstam as First Nugevia Brand Ambassador (GlobeNewswire) +8.11%
08:00AM	Jupiter Neurosciences Names Golf Legend Annika Sorenstam as First Nugevia Brand Ambassador (GlobeNewswire)
Jun-09-25 07:00AM	Jupiter Neurosciences Launches Nugevia: A Premium Longevity and Performance Supplement Line Grounded in Clinical Science (GlobeNewswire) +15.20%
Apr-08-25 08:00AM	Jupiter Neurosciences Highlights Upcoming Milestones in Shareholder Letter (GlobeNewswire)
Mar-07-25 10:10AM	Alliance Entertainment and Jupiter Neurosciences Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESS Newswire)
Mar-04-25 08:00AM	Jupiter Neurosciences and Aquanova AG Announce Strategic Collaboration to Develop Longevity and Healthspan Products (GlobeNewswire) +6.14%
Feb-04-25 09:25AM	Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones (GlobeNewswire) +11.36%
Feb-03-25 08:00AM	Jupiter Neurosciences Announces JOTROL Manufacturing Agreement with Catalent to Support Phase 2a Parkinson's Trial (GlobeNewswire) -5.84%
Jan-30-25 08:00AM	Jupiter Neurosciences Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson's Trial (GlobeNewswire) -8.20%
Jan-13-25 08:00AM	Jupiter Neurosciences Announces Strategic Focus on NLRP3 Pathway in Future JOTROL Trials (GlobeNewswire)
Dec-04-24 04:56PM	Jupiter Neurosciences, Inc. Announces Closing of $11 million Initial Public Offering (GlobeNewswire) +9.93%
Dec-02-24 07:00PM	Jupiter Neurosciences, Inc. Announces Pricing of $11 million Initial Public Offering and Listing on Nasdaq (GlobeNewswire)

Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company engaged in treating neuroinflammation with a current focus on CNS disorders and rare diseases. The firm offers JOTROL, an enhanced orally administered resveratrol formulation, designed to deliver therapeutically relevant, safe levels of resveratrol. The company was founded by Christer Rosen, Alexander Rosen, Claes Wahlestedt, Marshall Hayward, and Shaun P. Brothers in January 2016 and is headquartered in Jupiter, FL.

Co-FounderMr. Christer Rosen

MSMs. Alison D. Silva MA

Co-FounderDr. Marshall Hayward Ph.D.

Co-Founder & Chief Administrative OfficerMr. Alexander Rosen

CFO & SecretaryMr. Saleem Elmasri CPA

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

JUNS

Jupiter Neurosciences Inc

Upgrade your Finviz experience